

**Pelvic inflammatory disease in women;
improving diagnosis and better
understanding the disease process.**

by Rami Mazraani

Bachelor of Medical Science (Honours)

Thesis submitted in fulfilment of the requirements for
the degree of

Doctor of Philosophy

under the supervision of Associate Professor Wilhelmina Huston
and Dr. Catherine Burke

University of Technology Sydney
Faculty of Science

February 2021

CERTIFICATE OF ORIGINAL AUTHORSHIP

I, Rami Mazraani declare that this thesis, is submitted in fulfilment of the requirements for the award of Doctor of Philosophy in the school of life science at the University of Technology Sydney.

This thesis is wholly my own work unless otherwise referenced or acknowledged. In addition, I certify that all information sources and literature used are indicated in the thesis.

This document has not been submitted for qualifications at any other academic institution.

This research is supported by the Australian Government Research Training Program.

Production Note:

Signature: Signature removed prior to publication.

Date: 11/01/2021

List of keywords

Pelvic inflammatory disease, vaginal microbiome, host immune response, *Chlamydia trachomatis*, *Neisseria gonorrhoeae*, *Mycoplasma genitalium*, idiopathic

Acknowledgements

Firstly, I am forever grateful for these valuable opportunities that have been given to me throughout my tertiary education. However, when asked why I chose to do my PhD? The answer is still a mystery. My time as a PhD student has likely been the most difficult period in my life. It all started on an information night for research where I saw a new academic to the University of Technology, Sydney munching down on a muffin without anyone else talking to her. Maybe it was destiny or I was hungry, but since that moment a relationship has developed where I discovered a fond interest in female sexual health research. I honestly feel it would have been difficult without the amazing encouragement, personal and technical help to persevere and work through this, and teachings of Associate Professor Willa Huston. I am forever grateful!

Secondly to my partner Brad, you should have not let me continue my PhD, what were you thinking, I lost 80% of my hair, 80% of wrinkles grew, and I think I discovered a white hair when writing this. However, your support in listening about my research and issues has been non-stop. Thank you! Of course, I would like to extend my sincerest thanks to my family for helping me throughout the years of education. The friends I have made along the way have also been of great assistance, and I wish to personally thank Mark Thomas for teaching me cell culture, and my dearest friend William King for helping me consistently through correct analysis. I would like to thank my friends who have dealt with my complaints and rants, Jessica Pederson, Natalie Strange and Nicole Lima.

“Imagination is more important than knowledge. For knowledge is limited, whereas imagination embraces the entire world” – Albert Einstein

Disclaimer: Although this study and its works focus on PID in cis women, I would like to show my respect to my fellow LGBTQA+ community and understand that trans men can have pelvic inflammatory disease.

Table of Contents

List of keywords.....	ii
Acknowledgements	iii
Table of Contents	v
List of Figures	x
List of Tables	xi
Abstract.....	xiii
Chapter 1 - Introduction.....	1
1.1. PELVIC INFLAMMATORY DISEASE	2
1.1.1. Definition of Pelvic inflammatory disease.....	2
1.1.2. Prevalence of PID	2
1.1.3. Diagnosis of PID.....	6
1.1.4. Treatment of PID	10
1.1.4. Reproduction morbidities associated with a history of PID.....	14
1.2. EPIDEMIOLOGICAL AND DEMOGRAPHIC FACTORS ASSOCIATED WITH PID	15
1.3. AETIOLOGY	16
1.3.1. Idiopathic PID	16
1.3.2. Pathogen associated PID	18
1.3.3. <i>In vivo</i> animal models of STI's	32
1.3.4. Instrumentation induced PID.....	35
1.3.5. Occurrence of respiratory pathogens in PID	35
1.3. THE MICROBIOTA.....	36
1.3.1. The cervicovaginal microbiome	37
1.3.2. The functional microbiome	39
1.3.3. The dynamic temporal cervicovaginal microbiome	40
1.4. HOST IMMUNE FACTORS IN PID	42
1.5. KNOWLEDGE GAPS	45
1.6. PROJECT SCOPE	47
1.7. HYPOTHESIS AND AIMS	48
Chapter 2 - Case-Control study to investigate factors associated with pelvic inflammatory disease in NSW	51
2.1. INTRODUCTION.....	52

2.1.1. Epidemiological associations of women with pelvic inflammatory disease	52
2.1.2. Study design for the accurate diagnosis of cases for case-control studies	52
2.1.3. Considerations for questionnaire design to increase accuracy and participation	53
2.1.4. Demographics of people attending sexual health clinics	55
2.2. STUDY DESIGN AND METHODOLOGY	56
2.2.1. Recruitment protocol and criteria	56
2.2.2. Participant requirement protocol for Family Planning NSW study sites	58
2.2.3. Questionnaire data	61
2.2.4. Cairns Sexual Health Centre’s recruitment of a comparison sexual health group	63
2.2.5. Statistical analysis	65
2.2.6. Ethics and biosafety	65
2.3. RESULTS	66
2.3.1. Participant demographic dataset are consistent between the groups	66
2.3.2. Categorisation of PID aetiology	70
2.4. DISCUSSION	71
2.4.1. Demographic differences between groups are not apparent, supporting no unintended differences in recruitment	72
2.4.2. Sexually transmitted infections and the increased risk of subclinical PID	75
2.4.3. Differing aetiologies associated with PID	76
2.4.4. Limitations of recruitment and design	77
2.4.5. Conclusion	80
Chapter 3 - Profiling the microbes and microbial compositions within the vagina and cervix associated with pelvic inflammatory disease	81
3.1. INTRODUCTION	82
3.1.1. Understanding the cervicovaginal microbiome	82
3.1.2. Using Gram-stain to identify bacterial vaginosis – the Nugent score	83
3.1.3. <i>Lactobacillus</i> as part of the vaginal flora	86
3.1.4. Different cervicovaginal microbial community state types and disease	87
3.1.5. Microbial associations with pelvic inflammatory disease	89
3.2. MATERIALS AND METHODS	91
3.2.1. DNA extraction	91
3.2.2. Quality control and assurance	93

3.2.3. Preparation of 16S rRNA gene amplicons	93
3.2.4. 16S rRNA gene amplicons library preparation	99
3.2.5. Analysis of sequences using Qiime 2 and taxonomic identification of samples	100
3.2.6. Analysis of taxonomy and figure generation using R studio	101
3.2.7. Quantification of selected bacteria using quantitative real-time PCR..	102
3.2.8. Statistical analysis.....	106
3.3. RESULTS.....	106
3.3.1. DNA yield for every sample indicated successful extractions.....	106
3.3.2. Quality control allowed for adequate sequencing data.....	108
3.3.3. Relative abundance of microbial species in the cervicovaginal microbiome was different across groups, but consistent in each individual between the cervix and vagina	112
3.3.4. Quantitative PCR analysis demonstrates that the cases had lower levels of <i>L. crispatus</i>	120
3.4. DISCUSSION.....	122
3.4.1. PID cases were found to have a CST III and IV vaginal microbiome..	123
3.4.2. Limitations.....	126
3.4.3. Conclusion.....	128
Chapter 4 - Cervical host gene expression associated with pelvic inflammatory disease.....	130
4.1. INTRODUCTION.....	131
4.1.1. The immune system in the female genital tract.....	131
4.1.2. Pelvic Inflammatory disease as an immune condition.....	134
4.1.3. Gene expression during PID.....	135
4.1.4. Knowledge gaps in the host response in PID.....	138
4.2. MATERIALS AND METHODS.....	139
4.2.1. RNA extraction.....	140
4.2.2. Complementary DNA (cDNA) synthesis.....	141
4.2.3. Gene expression analysis using RT-qPCR.....	141
4.2.4. Statistical analysis.....	146
4.2.5. Analysis of ΔC_T and figure generation using R studio	148
4.3. RESULTS.....	148
4.3.1. RNA extraction from cervical swabs was successful using this pilot protocol.....	148
4.3.2. Normaliser genes allowed for intra-sample comparison.....	150
4.3.3. Intrasample heterogeneity in relative expression was evident.....	152

4.3.4. Lysozyme gene was expressed higher in cases then controls	154
4.1.1. Gene expression variability was associated with differing PID type	156
4.3.5. Gene expression variability was correlated with differing CST's.....	158
4.3.6. Comparative analysis of immune genes for case vs control suggested that expression of lysozyme is higher in women with PID.	163
4.3.7. Pathway analysis reveals bacterial detection and cell signalling pathway overrepresented in PID.	174
4.4. DISCUSSION.....	177
4.4.1. Variation in gene expression is naturally different between cells	
4.4.2. Lysozyme as an innate defence mechanism against pathogens	179
4.4.3. Limitations	180
4.4.4. Future considerations.....	183
4.4.4. Conclusion.....	184
Chapter 5 - Evaluation of genetic variants of Chlamydia, to examine if the loci are involved in virulence or pathogenesis that may interplay into pelvic inflammatory disease and other pathologies.....	186
5.1. INTRODUCTION.....	187
5.1.1. <i>Chlamydia</i> and pelvic inflammatory disease.....	187
5.1.4. Chlamydial and the murine model.....	188
5.1.2. Chlamydial pathogenicity	190
5.1.3. Chlamydial variants	190
5.2. MATERIALS AND METHODS.....	194
5.2.1. Buffers and reagents for chlamydial culture	194
5.2.2. Chlamydial culture conditions.....	196
5.2.3. Enumeration of inclusion forming units of chlamydia	199
5.2.4. Western blot	200
5.2.5. Infectivity of variants.....	201
5.2.6. Fatty acid extraction.....	202
5.2.7. Analysis of susceptibility to triclosan.....	205
5.2.8. Mouse model of chlamydial reproductive tract infection	205
5.2.10. Statistical and graphical analysis	208
5.3. RESULTS.....	209
5.3.1. Chlamydial purification showed no trace of host cell	209
5.3.2. <i>Chlamydia trachomatis</i> variants had a greater infectivity than the wild type	211
5.3.3. Chlamydial variants contained a distinct fatty acid profile from the wild type	213

5.3.4. <i>Chlamydial</i> variants 1B3 and 2A3 were detected to be less susceptible to triclosan than the wild type	216
5.3.5. Analysis of <i>in vivo</i> survival of chlamydial variants.....	217
5.3.6. Pathological analysis of <i>in vivo</i> chlamydial variants	220
5.4. DISCUSSION.....	224
5.4.1. Unsaturated fatty acids and their role in bacterial growth	224
5.4.2. Chlamydial variants survive <i>in vivo</i>	227
5.4.3. Conclusion.....	229
Chapter 6 . General discussion and future directions	231
6.1. The overall summary of findings	232
6.2. The cervicovaginal microbiome and connection to the host response.....	232
6.3. The cervicovaginal microbiome and antibiotics	237
6.4. Time to rethink PID treatment and diagnosis?	238
6.5. Future directions	240
6.6. Conclusion	242
Appendix A	245
Appendix B	257
Appendix C	268
Appendix D	270
Bibliography.....	282

List of Figures

Figure 1.1 Rates of hospitalisation for pelvic inflammatory disease (PID).....	5
Figure 1.2. The criteria for a diagnosis of PID.....	8
Figure 1.3. The chlamydial developmental cycle.....	19
Figure 1.4 The incidence per 1000 people of common STI's including Chlamydia, Gonorrhoea, Trichomoniasis and syphilis by regions of the world.....	25
Figure 1.5. Log10-transformed proportions of microbial taxa contained in the vaginal bacterial population as a cluster dendrogram with a heat diagram.....	38
Figure 1.6. The influences on the cervicovaginal microbiome dysbiotic or eubiotic state	41
Figure 1.7. Histological sections of endometrial tissue	44
Figure 2.1. Aetiologies of PID cases and demographic factors.	71
Figure 3.1. Image of representative vaginal smears that typify the Nugent score system.. ..	85
Figure 3.2. Forward and reverse reads quality plot generated by Qiime2.	111
Figure 3.3. Data quality control.....	112
Figure 3.4. Stacked bar graph showing relative abundance for the top 30 species	115
Figure 3.5. Cluster linkage dendrogram heat map of top 20 most abundant species in participants	118
Figure 3.6 Quantitative real-time PCR to establish quantities of selected bacterial species	121
Figure 3.7. Quantified bacterial chromosome copies according to PID aetiology.....	122
Figure 4.1. The unique female reproductive tract interactions with host defence, microbiome and sex hormones.....	133
Figure 4.2. Cluster dendrogram heat map of RT-qPCR analysis of immune gene expression in cervical samples	154
Figure 4.3. Lysozyme Cycle threshold change in case and control participants.....	155
Figure 4.4. Relative cycle threshold expression with differing PID causes.....	157
Figure 4.5. Relative cycle threshold expression with differing CST	160
Figure 4.6. Relative cycle threshold expression of cases and CST	162

Figure 4.7. Top 20 significant cellular functions that were present at higher gene levels in Cases	175
Figure 4.8. Top 5 pathways detected to be significantly different and with simplified interconnectivity	176
Figure 5.1. Constituent acids found in BAMES.....	204
Figure 5.2. Mouse model flow chart.....	207
Figure 5.3. Western blot membrane for detection of Chlamydial MOMP	210
Figure 5.4. Fatty acids found at different concentrations in variants when compared to the wild-type	215
Figure 5.5. Triclosan dose-response of chlamydial variants.....	217
Figure 5.6. Chlamydial IFU/mL shedding after infection.....	219
Figure 5.7. Mouse oviduct cross-sectional area	221
Figure 5.8. Haematoxylin and eosin-stained mouse upper reproductive tract.....	223
Figure 6.1. vaginal epithelium in a eubiotic state.....	234
Figure 6.2. Predicted functions of microbiota in the vaginal epithelium.....	236
Figure 6.3. Diagnostic protocol for PID for future consideration	245

List of Tables

Table 1.1. Treatment protocol for PID in Australia.....	13
Table 1.2. Community state types, dominant bacterial species and vaginal pH associated with these microbial profiles in women	39
Table 2.1. Study tubes with storage buffer used and their purpose.....	59
Table 2.2. Test group study tubes with storage buffer used and their purpose.....	64
Table 2.3. Demographic factors of participants who have PID, control and test groups	68
Table 3.1. Criteria for Nugent Score ^a	84
Table 3.2. Bacterial species found by culture and PCR in 831 women with endometritis ^a	90
Table 3.4 Forward and Reverse primers for PCR1 ^a	95

Table 3.5. Possible combinations of F and R primers for PCR1	95
Table 3.6. PCR 1 reaction set up	96
Table 3.7. PCR 1 cycling conditions	96
Table 3.8. Primer sequences for enrichment primers	98
Table 3.9. Enrichment PCR reaction set up	98
Table 3.10. Enrichment PCR cycling conditions	99
Table 3.11. Bacterial genus/species-specific primers used for quantitative PCR assays	103
Table 3.12. The synthetic DNA used to construct gene fragments for standard curve construction	104
Table 3.13. qPCR reaction combination	105
Table 3.14. qPCR cycling conditions	105
Table 3.15. Concentration of DNA per sample	107
Table 3.16. Read depth per control samples	110
Table 3.17. Read depth of the most abundant species detected within each participant	113
Table 3.18. Relative abundance of top 5 species and <i>Prevotella spp.</i> in each group...	117
Table 3.19. Proportions of microbial compositions of community state type	119
Table 4.1. Whole blood gene microarray used to classify STI induced PID	136
Table 4.2. Genes used in RT-qPCR array	142
Table 4.3. PCR cycling conditions	145
Table 4.4. RNA concentration per sample in ng/ μ L.....	149
Table 4.5. Housekeeping gene mean cycle threshold between study groups	151
Table 4.6. Analysis of housekeeping genes cycle threshold on the groups	151
Table 4.7. Genes significantly correlated with PID type	156
Table 4.8. Genes significantly correlated with CST (All participants).....	161
Table 4.9. Genes with significant ^a log ₂ fold change case compared to control.....	164
Table 4.10 Genes with significant ^a log ₂ fold change case compared to test group	165
Table 4.11. Analysis of ΔC_t between case and controls for all genes	167
Table 5.1. Genomic characteristics of JO146 resistant isolates*	197
Table 5.2. Percentage infectivity of the different variants	212
Table 5.3. Fatty acid detected within Chlamydial variants.....	213

Abstract

Pelvic inflammatory disease (PID) is a condition that involves inflammation of the upper genital tract in women that can be debilitating. This condition can result in reproductive health sequelae such as tubal factor infertility, ectopic pregnancy, and chronic pelvic pain. Diagnosis of PID is a complex and subjective clinical process. This includes a bimanual examination to test for cervical, uterine, and adnexal motion tenderness which is considered a critical diagnostic criterion to indicate PID. The current treatment protocol for PID raises concerns as it is immediately treated with several antibiotics prior to and regardless of infections diagnosed. The increase of antibiotic resistant bacteria in the world and the rise of multiple drug-resistant sexually transmitted infections may be at further risk from this treatment protocol. The antibiotics used for PID include ceftriaxone, cefotaxime, metronidazole, doxycycline, azithromycin and moxifloxacin, with a minimum of three used in conjunction. PID can be associated with sexually transmitted infection, respiratory pathogens, instrumentation (e.g. IUD), and/or an idiopathic aetiology.

This project conducted a prospective pilot study of women with PID, by comparing reproductive tract specimens from women with PID to healthy controls (Case-Control study design) and also further compared the findings in against a separate test group of women with asymptomatic or mild sexually transmitted infections. This involved three main objectives, the first being examining the bacterial compositions of

the female genital tract and their potential relationship with PID. Secondly, investigating expression of a selection of human immune genes for associations with PID. Lastly, the third objective involved characterising the pathogenicity of chlamydial variants using *in vivo* and *in vitro* methods, with a goal to determine if a mouse model could show large pathogenic differences that will establish a system of mouse infections ready to be adapted to looking for traits in chlamydial isolates from PID Cases or Controls.

Human research ethic committee approvals were granted and the recruitment resulted in 15 Cases, 31 Controls, and 13 Test group members (total of 59). Self-completed questionnaire data on behaviour and relevant medical history was received from a total of 59 participants. Biospecimens were successfully collected and received from 59 participants (resulting in 249 bio-specimens, consisting of 177 cervical and 59 vaginal swabs). The demographic, self-reported questionnaire and medical record review datasets were compiled and analysed for each of the groups to evaluate any differences in known risk factors for PID, or other substantial differences between the groups and no confounding epidemiological data was found. DNA was successfully extracted from cervical and vaginal biospecimens. Based on 16S rRNA gene amplicon sequencing, the cervicovaginal microbial composition was found to be variable across women regardless of disease status. However, quantitative PCR confirmed that a higher bacterial load of *Atopobium vaginae* and *Prevotella species* was associated with PID.

RNA was successfully extracted from the cervical swabs of participants. Attempts to extract RNA from the cervical swabs from the test group were unsuccessful, likely due to contamination and extended storage. The gene for lysozyme was found to be expressed

at higher levels in PID cases than controls, as the sole significantly different gene. Albeit, pathway analysis was conducted to identify pathways that had different gene expression levels between cases and controls, and significantly different pathways between cases and controls included those with cell communication and detection of bacteria and viruses.

Chlamydia trachomatis variants were examined to establish a framework approach to evaluate pathology of isolates. Fatty acids were successfully extracted from the bacterial strains and analysis found that there were different concentrations of four unsaturated acids relative to wild-type. Variants were found to have distinct susceptibilities to the fatty acid synthesis inhibitor type II (triclosan) compared to wildtype. Analysis of the *in vivo* properties (survival and reproductive tract pathology) of the variants found no significant differences compared to the wildtype in C57BL/6 and C3H/HeJ mouse vaginal infection models. Establishment of a suitable animal model for *C. trachomatis* virulence to profile if certain strains or isolates have distinct pathogenic traits requires further development.

Overall, this pilot study has established that the recruitment, specimen processing and analysis protocols are effective. The results indicate that there are potential microbiota that may influence the disease. Secondly, human immune gene expression profiles were found to correlate with PID, and these biomarkers could be used for future molecular diagnostic of PID with further supporting data. Finally, this study results and conclusions support that there is a need for a *in vivo* model of PID, especially in terms of investigating different organisms and potential pathogenic factors